Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMAB OTCMKTS:GNMSF NASDAQ:SMMT NASDAQ:SPK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMABGenmab A/S$27.99+0.6%$23.70$17.24▼$28.75$17.85B0.931.38 million shs1.54 million shsGNMSFGenmab A/S$285.00+0.3%$234.55$170.00▼$285.00$18.78B0.9265 shs5 shsSMMTSummit Therapeutics$18.94$25.37$15.55▼$36.91$14.07B-1.024.57 million shs4.53 million shsSPKSPK Acquisition$10.30$10.22$9.84▼$10.68$67.94M-0.0112,839 shs33,515 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMABGenmab A/S+0.61%+1.63%+20.08%+27.05%+4.05%GNMSFGenmab A/S+0.29%+3.83%+22.69%+28.09%+9.73%SMMTSummit Therapeutics0.00%-2.57%-29.04%-4.58%-40.68%SPKSPK Acquisition0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMABGenmab A/S$27.99+0.6%$23.70$17.24▼$28.75$17.85B0.931.38 million shs1.54 million shsGNMSFGenmab A/S$285.00+0.3%$234.55$170.00▼$285.00$18.78B0.9265 shs5 shsSMMTSummit Therapeutics$18.94$25.37$15.55▼$36.91$14.07B-1.024.57 million shs4.53 million shsSPKSPK Acquisition$10.30$10.22$9.84▼$10.68$67.94M-0.0112,839 shs33,515 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMABGenmab A/S+0.61%+1.63%+20.08%+27.05%+4.05%GNMSFGenmab A/S+0.29%+3.83%+22.69%+28.09%+9.73%SMMTSummit Therapeutics0.00%-2.57%-29.04%-4.58%-40.68%SPKSPK Acquisition0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMABGenmab A/S 2.70Moderate Buy$39.2540.23% UpsideGNMSFGenmab A/S 0.00N/AN/AN/ASMMTSummit Therapeutics 2.65Moderate Buy$33.7978.38% UpsideSPKSPK Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SPK, GNMSF, GMAB, and SMMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025SMMTSummit TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/8/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.009/3/2025SMMTSummit TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.009/3/2025SMMTSummit TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.009/3/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$40.009/2/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.008/27/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$44.00 ➝ $50.008/19/2025SMMTSummit TherapeuticsSummit RedstoneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$21.008/19/2025GMABGenmab A/SZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/19/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$40.008/18/2025SMMTSummit TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$21.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMABGenmab A/S$3.12B5.75$1.53 per share18.35$8.04 per share3.48GNMSFGenmab A/S$3.12B6.03$15.23 per share18.71$80.53 per share3.54SMMTSummit Therapeutics$700K20,099.40N/AN/A$0.53 per share35.74SPKSPK AcquisitionN/AN/AN/AN/A($0.19) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMABGenmab A/S$1.14B$1.9914.0715.721.6237.53%21.03%16.98%11/6/2025 (Estimated)GNMSFGenmab A/S$1.14B$19.9214.31∞N/A37.53%21.03%16.98%11/6/2025 (Estimated)SMMTSummit Therapeutics-$221.32M-$1.01N/AN/AN/AN/A-208.64%-181.28%10/29/2025 (Estimated)SPKSPK Acquisition-$420KN/A0.00∞N/AN/AN/A-1.95%N/ALatest SPK, GNMSF, GMAB, and SMMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025SMMTSummit Therapeutics-$0.10-$0.76-$0.66-$0.76N/AN/A8/7/2025Q2 2025GMABGenmab A/S$0.39$0.54+$0.15$0.54$5.77 billion$925.00 million8/7/2025Q2 2025GNMSFGenmab A/S$3.99$5.42+$1.43$5.42$949.06 million$925.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMABGenmab A/SN/AN/AN/AN/AN/AGNMSFGenmab A/SN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ASPKSPK AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMABGenmab A/SN/A6.226.20GNMSFGenmab A/SN/A6.226.20SMMTSummit TherapeuticsN/A5.135.13SPKSPK AcquisitionN/A4.644.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMABGenmab A/S7.07%GNMSFGenmab A/SN/ASMMTSummit Therapeutics4.61%SPKSPK Acquisition19.64%Insider OwnershipCompanyInsider OwnershipGMABGenmab A/S1.54%GNMSFGenmab A/S1.54%SMMTSummit Therapeutics84.90%SPKSPK Acquisition22.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMABGenmab A/S2,682641.59 million631.71 millionOptionableGNMSFGenmab A/S2,68266.08 million65.06 millionNot OptionableSMMTSummit Therapeutics110742.85 million112.17 millionOptionableSPKSPK Acquisition2,0216.60 million5.12 millionNot OptionableSPK, GNMSF, GMAB, and SMMT HeadlinesRecent News About These CompaniesASX 200 telco marches higher on $820 million asset saleJuly 11, 2022 | fool.com.auP&W, Embraer complete first full-SAF test flight with E195-E2July 2, 2022 | flightglobal.comFPiezoelectric Tiles Market Research Report by Material, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19June 27, 2022 | uk.finance.yahoo.comSPK Acquisition Corp. Cl AMay 21, 2022 | barrons.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPK, GNMSF, GMAB, and SMMT Company DescriptionsGenmab A/S NASDAQ:GMAB$27.99 +0.17 (+0.61%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$28.20 +0.21 (+0.75%) As of 06:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Genmab A/S OTCMKTS:GNMSF$285.00 +0.83 (+0.29%) As of 09/15/2025 12:37 PM EasternGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Summit Therapeutics NASDAQ:SMMT$18.94 0.00 (0.00%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$18.90 -0.04 (-0.21%) As of 06:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.SPK Acquisition NASDAQ:SPKSPK Acquisition Corp. intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on operating businesses in the telecommunications, media, and technology sectors in Asia. The company was incorporated in 2020 and is based in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
